Jane Street
RGLS

Jane Street’s Regulus Therapeutics RGLS Stock Holding History

Jane Street’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,800
Closed -$85.8K – 10056
2024
Q1 		$85.8K Buy
+29,800
New +$48.6K ﹤0.01% 8580

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's RGLS Position: Q4 2024 in Review

Jane Street sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 29,580 shares — an estimated $46.4K sold.

Jane Street first reported a position in RGLS in Q1 2019 and held it in 9 quarters. The position peaked at $64K in Q1 2019. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

  • Jane Street reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jane Street sold 29,580 Regulus Therapeutics shares in Q4 2024, an estimated $46.4K.
  • Jane Street first reported a position in Regulus Therapeutics in Q1 2019 and held it in 9 quarters.
  • Jane Street's Regulus Therapeutics position peaked at $64K in Q1 2019.
  • 69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Jane Street's 13F filing for Q4 2024, filed 14 Feb 2025.